Clinical Trial Update: Impact of the EXOMIND (BTL-699-2) on the Brain Reward Pathway [NA]

View source ↗

Summary

The EXOMIND (BTL-699-2) trial examining its impact on the brain reward pathway in binge eating disorders remains active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Binge Eating Disorder

Drugs mentioned

• EXOMIND (BTL-995)

Snippet

Sponsor: BTL Industries Ltd. | Conditions: Binge Eating Behaviour, Binge Eating/Loss of Control Eating | NA | Status: ACTIVE_NOT_RECRUITING